PITTSBURGH, Oct. 29, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to Forbes' World's Top Companies for Women 2024 List. This award is presented in collaboration with Statista, the world-leading statistics portal and industry ranking provider. "At Viatris, diverse perspectives drive innovation and our ability to make an impact, as we empower people worldwide to live healthier at every stage of life," said Andrew Enrietti, Chief People O ...

PITTSBURGH, Oct. 29, 2024 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the company will participate in two upcoming healthcare conferences.Details of the presentations can be found below:UBS Global Healthcare Conference Date: Tuesday, November 12, 2024 Time: 8:45 a.m. PT / 11:45 a.m. ET Location: Terranea Resort in Rancho Palos Verdes, California Format: Fireside chat with Viatris executivesJeffries London Healthcare Conference  Date: Thursday, November 21, ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

THE WOODLANDS, Texas, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Viatris Inc. (Nasdaq: VTRS) has obtained an exclusive license from Lexicon to commercialize sotagliflozin outside of the United States and Europe in all indications. Lexicon retains sole commercialization rights for sotagliflozin in all indications in the United States and Europe. Sotagliflozin was approved by the U.S. Food and Drug Administration in May 2023 to reduce the risk of cardio ...

Continues to Expand Viatris' Innovative Portfolio in Cardiovascular Diseases Leverages Viatris' Unique Global Infrastructure and Expertise Includes Opportunities to Leverage the Potential of Sotagliflozin to Additional Indications PITTSBURGH, Oct. 16, 2024 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it has entered into an exclusive licensing agreement with Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) for sotagliflozin in all markets outside of the United States ...

Treatment with once-daily EFFEXOR® met primary and all secondary efficacy endpoints in outpatient adults with GAD EFFEXOR® was generally well tolerated, consistent with its known safety profile Pharmaceuticals and Medical Devices Agency (PMDA) submission targeted for 2025 PITTSBURGH and TOKYO, Oct. 9, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced positive top-line results of its Phase 3 study (B2411367) in Japan evaluating the safety and efficacy of EFFEXOR® ...

PITTSBURGH, Sept. 18, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today the pricing terms of the previously announced cash tender offer (the "Maximum Tender Offer") of its subsidiary Utah Acquisition Sub Inc. ("UAS") for up to an increased maximum aggregate principal amount of $575,003,000 of its outstanding 3.950% Senior Notes due 2026 (the "Maximum Tender Offer Notes") validly tendered and not validly withdrawn at or prior to the Early Tender Date (as defined bel ...

Tender Offer Details - Viatris Inc announced the early tender results of its subsidiary Utah Acquisition Sub Inc's cash tender offer, increasing the maximum aggregate principal amount from $450,000,000 to $575,003,000 for its 3.950% Senior Notes due 2026 [1] - The aggregate principal amount of Maximum Tender Offer Notes validly tendered and not withdrawn by the Early Tender Date was $1,449,950,000, exceeding the Maximum Tender Cap of $575,003,000 [2][3] - UAS will accept tendered notes on a pro rata basis with a proration factor of 39.7% due to oversubscription [3][5] Tender Offer Terms and Timeline - The total consideration for accepted notes will be determined at 10:00 am on September 18, 2024, including an Early Tender Payment of $30 per $1,000 principal amount [4][6] - The Maximum Tender Early Settlement Date is anticipated to be September 20, 2024 [7] - The Maximum Tender Offer will expire at 5:00 pm on October 2, 2024, unless extended or terminated earlier [8] Company Financial Activities - Viatris satisfied and discharged the indenture for its 1.650% Senior Notes due 2025 on September 16, 2024 [11] - Mylan Inc issued a notice of redemption for all outstanding 2.125% Senior Notes due 2025, with redemption expected to be completed by October 16, 2024 [11] Company Overview - Viatris is a global healthcare company combining generics and brands to address healthcare needs worldwide, supplying medicines to approximately 1 billion patients annually [16] - The company has a diverse portfolio of medicines and a global supply chain, with headquarters in the US and global centers in Pittsburgh, Shanghai, and Hyderabad [16]

PITTSBURGH, Sept. 16, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report its third quarter 2024 financial results on Thursday, November 7, 2024, before the open of the U.S. financial markets. Chief Executive Officer Scott A. Smith and other Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for internati ...

PITTSBURGH, Sept. 10, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today that the previously announced cash tender offers (the "Any and All Tender Offers" and each, an "Any and All Tender Offer") of Viatris and its subsidiary Mylan Inc. ("Mylan" and, together with Viatris, the "Offerors" and each, an "Offeror") for any and all of the outstanding 1.650% Senior Notes due 2025 issued by Viatris (the "Viatris Notes") (CUSIP No. 92556VAB2/ISIN US92556VAB27) and any and a ...